KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial – study protocol

BMC Complementary and Alternative Medicine

Seong-Gyu Ko³  Yong-Cheol Shin³  Bo-Hyoung Jang³  Ho-Yeon Go¹  Soobin Jang³  So-Mi Oh³  Jeong-Su Park³  Sunju Park²  Chunhoo Cheon³ 

[1] Department of Internal Medicine, College of Korean Medicine, Semyung University, Bongbang-dong, Chungju 380-960, Republic of Korea;Department of Preventive Medicine, College of Korean Medicine, Daejeon University, 62 Daehak-ro, Dong-gu, Daejeon 300-716, Republic of Korea;Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea

关键词: Herbal medicine;    Natural product;    Functional food;    Atopic dermatitis;   

Others  :  1220482
DOI  :  10.1186/1472-6882-13-335

 received in 2013-10-25, accepted in 2013-11-22,  发布年份 2013

【 摘 要 】

Background

Atopic dermatitis is a chronic inflammatory skin disease with a high prevalence rate and a large socioeconomic cost. There are many treatments for atopic dermatitis, such as antihistamine, tacrolimus and corticosteroids. However, due to concern about the adverse effects, many patients seek alternative treatments. In this context, natural products are gaining interest. KM110329 is a functional food consisting of four herbs that are beneficial to skin health. The purpose of this study is to assess the efficacy and safety of KM110329 for atopic dermatitis.

Methods/design

This study is a randomised, double-blind, placebo-controlled and multicentre trial of KM110329. For this study, we will recruit 66 atopic dermatitis patients of both sexes, with ages ranging from 18 to 65, from three university hospitals. The participants will receive either KM110329 or a placebo twice a day for 8 weeks. The primary end point will be a change in the scoring atopic dermatitis (SCORAD) index. The secondary end points will include changes to the dermatology life quality index (DLQI) and transepidermal water loss (TEWL), among others. The outcomes will be measured at every visit. The study will be continued for 8 weeks and will include five visits with each subject (at screening and at 0, 1, 4 and 8 weeks).

Discussion

This trial will provide research methodologies for evaluate clinical efficacy and safety of KM110329 in adult patients with atopic dermatitis. In addition, we will evaluate the changes in the general skin health status and quality of life.

Trial registrations

ClinicalTrials.gov NCT01692093.

【 授权许可】

   
2013 Cheon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006, 61:969-987.
• [2]Williams HC: Clinical practice. Atopic dermatitis. N Engl J Med 2005, 352:2314-2324.
• [3]Chrostowska-Plak D, Reich A, Szepietowski JC: Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2012, 27:239-242.
• [4]Boo YM, Seo BI, Lee JH, Choi HY, Kwon DY: Herbology. Seoul, Korea: Younglimsa; 2011.
• [5]WHO Western Pacific Region: WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region. Manila, Philippines: WHO; 2007.
• [6]Shin T-Y, Kim S-H, Lee E-S, Eom D-O, Kim H-M: Action of Rubus coreanus extract on systemic and local anaphylaxis. Phytother Res 2002, 16:508-513.
• [7]Park JH, Oh S-M, Lim SS, Lee YS, Shin H-K, Oh Y-S, Choe N-H, Park JHY, Kim J-K: Induction of heme oxygenase-1 mediates the anti-inflammatory effects of the ethanol extract of Rubus coreanus in murine macrophages. Biochem Biophys Res Commun 2006, 351:146-152.
• [8]Sung Y-Y, Yoon T, Jang JY, Park S-J, Kim HK: Topical application of Rehmannia glutinosa extract inhibits mite allergen-induced atopic dermatitis in NC/Nga mice. J Ethnopharmacol 2011, 134:37-44.
• [9]Kim H, Lee E, Lee S, Shin T, Kim Y, Kim J: Effect of Rehmannia glutinosa on immediate type allergic reaction. Int J Immunopharmacol 1998, 20:231-240.
• [10]Lee JS, Kim IS, Kim JH, Kim JS, Kim DH, Yun CY: Suppressive effects of Houttuynia cordata Thunb (Saururaceae) extract on Th2 immune response. J Ethnopharmacol 2008, 117:34-40.
• [11]Li W, Zhou P, Zhang Y, He L: Houttuynia cordata, a novel and selective COX-2 inhibitor with anti-inflammatory activity. J Ethnopharmacol 2011, 133:922-927.
• [12]Lee H-S, Kim SK, Choi M-S, Lee S, Han J-B, An H-J, Um J-Y, Kim H-M, Lee N-Y, Bae H, Min B-I: The bark of Betula platyphylla var. japonica inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. J Ethnopharmacol 2008, 116:270-278.
• [13]Oh SR, Um JY, Choi HJ, Im CK, Kim KJ, Jung JW, Jeong GS, Hong SH, Kim SJ: Betula platyphylla attenuated mast cell-mediated allergic inflammation in vivo and in vitro. Life Sci 2012, 91:20-28.
• [14]Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J: EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012, 67:99-106.
• [15]Shin S-H, Kim J-H, Kim M-B, Yoon H-J, Lyu S-A, Lee S-Y, Lee M-Y, Kim K-K, Ko W-S: A Clinical Research about the Effects of Seunggaltang on Patients with Atopic Dermatitis. J Korean Orient Med Ophthalmol Otolaryngol Dermato 2007, 20:199-212.
• [16]Korea Health Industry Development Institute: Analysis and Prospect for the Market of Health Functional Foods and Presentation of Strategy for Industry Development in Korea. Seoul, Korea: Korea Food & Drug Administration; 2007.
• [17]Kim NK, Lee DH, Seo HS, Sun SH, Oh YL, Kim JE, Yoon IH, Seo ES, Shim GS, Zaslawski C: Hwangryunhaedoktang in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial–study protocol. BMC Complement Altern Med 2011, 11:68. BioMed Central Full Text
• [18]Korea Food and Drug Administration: The research on evaluation endpoint development for clinical trial of herbal medicinal products about atopic dermatitis and allergic rhinitis. Seoul: KFDA; 2008.